BackAlar Pharmaceuticals Overview

Alar Pharmaceuticals Total Assets

Track Alar Pharmaceuticals's total assets ($2.4B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$2.45B
↓ 2.99% YoYΔ $-75.59M vs prior year quarter

Peer trimmed avg / median

Loading

Alar Pharmaceuticals Total Assets History

Loading

Alar Pharmaceuticals vs. peers: Total Assets Comparison

Loading

Alar Pharmaceuticals Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Alar Pharmaceuticals (6785.TWO) FAQ

Alar Pharmaceuticals (6785.TWO) currently reports a total assets of $2.4B as of June 2026. That compares with $2.5B in the prior-year period — down 3.0% year over year. Use the charts on this page to explore Alar Pharmaceuticals's total assets history and peer comparisons.

Alar Pharmaceuticals's total assets decreased from $2.5B to $2.4B — a 3.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Alar Pharmaceuticals reported $2.4B in total assets as of June 2026. That compares with $2.5B in the prior-year period — down 3.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total assets of $2.4B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Alar Pharmaceuticals, and consider following 6785.TWO for alerts when major investors trade the stock.